Balbir Brar

Biography

 Dr. Brar has 25 years of drug development experience working with major pharmaceutical companies. This included 16 years at Allergan (NYSE:AGN) as VP Drug Safety, Metabolism, Pharmacokinetics, Life Sciences and Drug Candidate Optimization where he was responsible for building a new R&D facility at a cost of $75 million; staffing the facility with 100 scientists, and managing over 20 projects in all major therapeutic areas with an annual budget in excess of $20 million. His tenure at Allergan resulted in regulatory submission of 50 IND's/510K's and world-wide approval of 8 major NDA's that later became very successful drugs currently on the market, including: Alphagan, Lumigan, Tazarotene and Botox. During this period he developed strong contacts with world-wide regulatory agencies and contract research organizations. Through strong technical strengths and negotiations he reduced the drug approval time by a number of years, for an early entry to the market, thus changing Allergan from a small operation to a major pharmaceutical of over $2 billion annual sales. Prior experience includes SmithKline & Beckman (NYSE: GSK) as a Sr. Director of Drug Safety, where he participated in the early stage development and regulatory submission of a number of IND's. As a Sr. Scientist at Lederle /Wyeth (NYSE: WYE) he developed Azmacort for asthma and topical Aristocort, both multimillion dollar products currently on the market. Dr. Brar obtained his Ph.D. in Toxicology/Pathology from Rutgers and holds a DVM from India.

Research Interest

 BUSINESS AND MANAGEMNET